SUNPHARMA
Sun Pharmaceutical Industries Limited
Each stock's 10,000-path forecast, rendered as light.
Sun Pharmaceutical Industries Limited (SUNPHARMA) Stock Analysis & Case Study
Is SUNPHARMA a good buy? The data-driven verdict.
Sun Pharmaceutical Industries Limited (SUNPHARMA) trades at ₹1,945,on the numbers it worth a closer look, a Downstox Snapshot Score of 62/100.
On the numbers, Sun Pharmaceutical Industries Limited (SUNPHARMA) worth a closer look, a Downstox Snapshot Score of 62/100, weighing premium at 36.9× earnings, ROE of 16.0%, a 71% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
SUNPHARMA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How SUNPHARMA ranks against the 2,373 companies in our screener
- SUNPHARMA's market cap of 4.67L Cr ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUNPHARMA's book value of ₹348 ranks in the 84th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUNPHARMA's promoter holding of 54.5% ranks in the 40th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUNPHARMA's 3-year profit (PAT) growth of 13.0% ranks in the 46th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUNPHARMA's 3-year revenue growth of 10.0% ranks in the 50th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUNPHARMA's debt-to-equity ratio of 0.06x is lower than 84% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is SUNPHARMA overvalued? SUNPHARMA P/E vs its Pharma
SUNPHARMA's P/E of 36.9× sits above the Pharma peer median of 33.0×, so on earnings it screens richer than peers, while its 0.82% dividend yield is above the peer median of 0.68%.
SUNPHARMA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of SUNPHARMA history (9%/yr drift, 20%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| SUNPHARMA 2027 | ₹1,694 | ₹2,180 | ₹2,805 | +12% |
| SUNPHARMA 2028 | ₹1,704 | ₹2,443 | ₹3,501 | +26% |
| SUNPHARMA 2029 | ₹1,779 | ₹2,737 | ₹4,211 | +41% |
| SUNPHARMA 2030 | ₹1,859 | ₹3,067 | ₹5,062 | +58% |
| SUNPHARMA 2031 | ₹1,954 | ₹3,438 | ₹6,048 | +77% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability SUNPHARMA goes up, or doubles?
The bull case for SUNPHARMA
- SUNPHARMA's return on equity of 16.0% ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUNPHARMA's return on capital employed of 20.5% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 71% chance the price is higher in a year, with a median target of ₹2,180 (+12%).
- Relatively low volatility (20%/yr), a steadier ride than the typical mid/small-cap.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹4,211.
The bear case & risks
- SUNPHARMA's P/E of 36.9x is lower than 37% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,779.
SUNPHARMA volatility & expected range, how bumpy is the ride?
Over the last 9.8 years SUNPHARMA compounded at 9%/year with annualized volatility of 20%. That volatility implies a 1-year 80% range of ₹1,694-₹2,805, the honest backbone behind any single price target.
SUNPHARMA price forecast, the full 60-month probability fan
SUNPHARMA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds SUNPHARMA hits common targets within the simulated horizon?
Full multi-horizon detail on the SUNPHARMA price target & forecast page.
SUNPHARMA Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. SUNPHARMA scores 6/8, mixed financial health.
SUNPHARMA MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy SUNPHARMA with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 23.00% | 4.3× |
| Zerodha | 22.60% | 4.4× |
| Groww | 22.56% | 4.4× |
| Dhan | 22.00% | 4.5× |
| Kotak NeoCHEAPEST | 20.00% | 5.0× |
| Paytm MoneyCHEAPEST | 20.00% | 5.0× |
| Pocketful | 26.50% | 3.8× |
| Anand Rathi | 26.50% | 3.8× |
| Bajaj Broking | 23.00% | 4.3× |
| Share India | 26.50% | 3.8× |
Compare every broker on the SUNPHARMA MTF page.
SUNPHARMA vs peers,Pharma comparison
| Stock | P/E | Div yield | Market cap |
|---|---|---|---|
| SUNPHARMA (this stock) | 36.9× | 0.82% | ₹4.67L Cr |
| DIVISLAB | 73.7× | 0.36% | ₹2.20L Cr |
| DRREDDY | 30.4× | 0.68% | ₹97,824 Cr |
| CIPLA | 33.0× | 0.89% | ₹1.18L Cr |
| LUPIN | 18.2× | 0.76% | ₹1.08L Cr |
| AUROPHARMA | 25.5× | 0.24% | ₹96,297 Cr |
| BIOCON | 95.5× | 0.12% | ₹69,482 Cr |
Fundamentals from Screener.in, as of 9 Aug 2026
About Sun Pharmaceutical Industries Limited: sector, index & market-cap context
Sun Pharmaceutical Industries Limited (SUNPHARMA) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 50 index, with a market capitalisation of ₹4.67L Cr. See more stocks on our screener.
How the SUNPHARMA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Sun Pharmaceutical Industries Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
SUNPHARMA analysis, FAQs
Is Sun Pharmaceutical Industries Limited (SUNPHARMA) a good buy?
On the numbers, Sun Pharmaceutical Industries Limited (SUNPHARMA) worth a closer look, a Downstox Snapshot Score of 62/100, weighing premium at 36.9× earnings, ROE of 16.0%, a 71% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is SUNPHARMA overvalued or undervalued?
SUNPHARMA trades at 36.9× earnings versus a peer median of 33.0×, so it screens richer than its Pharma peers.
What is the SUNPHARMA share price target for 2031?
SUNPHARMA's probability-weighted 2031 median target is ₹3,438, with an 80% range of ₹1,954-₹6,048 (10,000-path Monte-Carlo).
What is the probability SUNPHARMA doubles in 5 years?
The modelled probability of SUNPHARMA reaching ₹3,890 (2×) within 5 years is 39%.
What is the bull case for SUNPHARMA?
SUNPHARMA's return on equity of 16.0% ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. SUNPHARMA's return on capital employed of 20.5% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A 10,000-path probability model puts a 71% chance the price is higher in a year, with a median target of ₹2,180 (+12%).
What are the risks in SUNPHARMA?
SUNPHARMA's P/E of 36.9x is lower than 37% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.